 |
ONCOLOGY FOCUS
PRODUCT CANDIDATES
|
|
Lead Product Candidates
ADVENTRX is currently focused primarily on advancing ANX-530 and ANX-514, which are novel emulsion formulations of currently marketed chemotherapy drugs. The Company believes ANX-530 and ANX-514 may improve the safety of and have greater commercial potential than the currently marketed reference products, Navelbine and Taxotere, respectively, by:
- Improving their safety and reducing the incidence and severity of adverse effects; and
- Increasing their pharmacoeconomics and convenience to healthcare practitioners and patients.
Reformulating existing pharmaceutical products is an increasingly common product lifecycle-management technique. Between 2002 and 2005, nearly 40% of the products launched by the top 50 pharmaceutical manufacturers were reformulations. Finding new markets for and ways to modify and improve existing products is often an essential element of pharmaceutical companies' efforts to maintain or grow revenues in the face of patent expirations and competitive pressures.
Navelbine and taxotere are intravenously-injected chemotherapy drugs commonly used to treat solid tumors. We believe the current formulations of these drugs have limitations that present opportunities for improvement. We are developing novel ways to formulate the active ingredient underlying each of these drugs that we believe may improve their safety profiles without adversely affecting efficacy. In addition, we believe our formulations may provide benefits to patients and practitioners that do not manifest themselves in traditional measures of safety or efficacy.
Other Product Candidates
In addition to ANX-530, ANX-514 and CoFactor, we hold rights to a number of other compounds that from time to time we will evaluate for future preclinical and clinical development. Currently, our efforts and the majority of our resources are focused on advancing our lead emulsion formulation product candidates, ANX-530 and ANX-514, as well as CoFactor. Until we have successfully achieved particular milestones with respect to one or more of these product candidates (for example, partnering the product candidate outside the U.S. or globally, obtaining marketing approval in the U.S. or establishing a specialized sales force and related infrastructure), we do not anticipate allocating substantial resources toward other product candidates or development options.
|
|
|
